baber/WOPTO huggingface dataset:
Patent JP-2812431-B2 (JP)
IPC: C07D211/20
Filed: 1996-07-31
Granted: 1998-10-22
Abstract: Sulphonamido-phenylalkanoic acid derivs. of formula (I), and their salts, are new. In (I), R1 = Het1 opt. substd. NR6R7, R6R7NC- (=NR6)- R6R7NC(=NR6)NH-, R6C(=NR7)NR7- or a gp. (a) or (b); Het1 = a 4-8 member heterocyclic ring contg. 1-4 heteroatoms from N, O, S; R6, R7 = H, 0-10C alkyl or cycloalkyl, both opt. substd. Het2 = 1-4C alkanoylamino, 1-6C alkoxycarbonyl, 0-6C alkylamino; 1-10C alkylsulphonylamino, 4-10C aralkylsulphonylamino, 4-10C aralkyl, 1-10 1-10C alkaryl, 1-10C alkylthio 4-10C aralkylthio, 1-10C alkylsulphinyl, 4-10C aralkylsulphinyl, 1-10C alkylsulphonyl, 4-10C aralkylsulphonyl, aminosulphonyl, 1-10C alkylaminosulphonyl, 4-10C aralkylsulphonylamino, oxo, thio, or 1- or 2-ethenyl or 3- propenyl, all opt. substd.; "alkyl" = from alkane, alkene or alkyne; alkoxy = O-alkyl; aralkyl and alkaryl contain alkyl as defined above and aryl defined below; Het2 = a 5 or 6 membered satd. heterocyclic ring contg. 1-4 heteroatoms from N, O, S; aryl = a mono- or poly-cyclic ring system of 5- and 6-membered aromatic rings contg. 0-4 heteroatoms from N, O, S; R2, R3 = H, aryl, or 0-10C alkyl or cycloalkyl both opt. substd.; R4 = aryl, 1-10C alkyl or cycloalkyl, 4-1UC aralkyl, 1-10C alkoxyalkyl, 1-10C alkaryl, 1-10C alkylthioalkyl, 1-10C alkoxythioalkyl, 1-10C alkylamino, 4-10C aralkylamino, 1-10C alkanoylamino, 4-10C aralkanoylamino, 1-10C alkanoyl, 4-10C aralkanoyl, or 1-10C carboxyalkyl opt. substd. R5 = Het1, COR8, or CSR8; R8 = e.g. OH, 1-10C alkyloxy, 1-10C alkaryloxy, etc. X. Y, Z are opt. substits. and = NR6, O, S, SO, CO, CS CH(OH), SO2, CR6=CR7, CC, Het1, (opt. substd. at any atom with R6), aryl, CONR6, NR6CO, NR6SO2, or SO2NR6; m = 0-10; n = 0-10; and p = 0-3.
Patent JP-2953607-B2 (JP)
IPC: A61K31/785
Filed: 1994-09-07
Granted: 1999-09-27
Abstract: The present invention provides a novel fine milled form of a known pharmaceutical composition, colestipol hydrochloride. This fine milled form of colestipol hydrochloride yields pharmaceutically elegant dosage forms exhibiting increased potency, including non-gritty oral powders and high dose oral tablets (e.g., 1000 mg tablets). Conventional colestipol hydrochloride was heretoforth available in spherical granules which produced less elegant (gritty) oral suspensions and oral tablets with substantially lower doses of drug (e.g., ca 500 mg).
Patent JP-H0815440-B2 (JP)
IPC: C12N1/21
Filed: 1985-10-04
Abstract: Direct linkage of DNA encoding prokaryotic signals such as E. coli enterotoxin with DNA encoding mature eukaryotic proteins, followed by transformation and culture of bacterial hosts characterized by a periplasmic space, yields substantial amounts of periplasmic mature protein. Constitutively promoted gram negative bacterial mutants are transformed with vectors containing DNA encoding a secretable heterologous protein under the transcriptional control of a constitutively promoted promoter. Periplasmic proteins are recovered from transformed gram negative bacteria by a process comprising freezing and thawing the cells. Advantages are obtained by culturing the cells in phosphate-limiting media and by killing the cells prior to separation of periplasmic proteins.
Patent JP-H0465409-B2 (JP)
IPC: G06F15/78
Filed: 1984-11-28
Abstract: PURPOSE:To monitor the specific contents of a data memory while allowing real time operation by outputting the contents of a specified RAM to the external in a machine cycle in which a CPU does not use a data bus. CONSTITUTION:In the machine cycle in which the data bus 2100 is not used, the CPU1 outputs logical '1' to a control line 1000. Receiving the output, a multiplexer 3 supplies an address supplied through a monitor address input line 3000 as an address specification signal of a data memory 2. Consequently, the contents of the address in the specified memory 2 are latched by a data register 4. Thereby, the data on the specified address in the memory 2 are latched by the register 4 every appearance of the machine cycle in which the CPU1 does not use the bus 2100 by supplying the address specification signal from the external through the line 3000. Thus, whether the contents of the memory 2 are changed or not can be checked by reading out the contents of the register 4 while referring the signal on the line 1000.
Patent JP-2590059-B2 (JP)
IPC: G01N33/52
Filed: 1985-11-14
Granted: 1997-03-12
Abstract: A chromatographic device (20) comprises a housing (22), a strip (24) of bibulous material non-removably confined in the housing (22). The strip (24) has a length and width only slightly less than the length and width of the inner walls of the housing. The inner walls of the housing have means for supportively confining the strip in the housing. The strip is confined so that (i) the front and back of the strip are essentially free from contact with the walls of the housing and (ii) the capillary action of the strip remains substantially unchanged, and (iii), where the strip is paper, the strip is allowed to expand as it is tranversed by the liquid medium. The bottom end of the housing has an opening for enabling contact of a portion of the strip with the liquid medium. The housing further has a slot for visually observing the strip and can also have a scale (56) and opening (58) to assist in determining the result of a chromatographic test. The present device has particular appliction in immunochromatography for the determination of the presence of an analyte suspected of being pesent in a sample.
Patent JP-2670383-B2 (JP)
IPC: G06F17/30
Filed: 1990-09-28
Granted: 1997-10-29
Abstract: A prefix index tree structure for locating data records stored through keys related to information stored in data records. Each node includes a prefix field for a prefix string of length p of the longest string of key characters shared by all subtrees of the node and a data record field for a reference to a data record whose key is completed by the prefix string. A node may include one or more branch fields when the prefix string is a prefix of keys stored in at least one subtree of the node, with a branch field for each distinct p+1<st> key character in the keys, wherein each p+1<st> key character is a branch character. Each branch field includes a branch character and a branch pointer field for a reference to a node containing at least one key whose p+1<st> character is the branch character. Each node further includes a field for storing the number of key characters in the prefix string and a field for storing the number of branch fields in the node. Also disclosed are methods for constructing and searching a prefix index tree of the present invention, and for inserting nodes into the tree and deleting nodes from the tree.
Patent JP-3072266-B2 (JP)
IPC: H01Q1/08
Filed: 1996-10-09
Granted: 2000-07-31
Abstract: A retractable antenna system for an electrical device includes a rod antenna movable to an extended position or to a retracted position, an electrical coil carried by one end of the rod antenna and movable therewith to the extended and retracted positions, and a coil antenna carried by the electrical device coaxially with the rod antenna such as to enclose the electrical coil and to be electromagnetically coupled thereto in the retracted position of the rod antenna and electrical coil. <IMAGE>
Patent JP-3293820-B2 (JP)
IPC: C12Q1/68
Filed: 1986-12-12
Granted: 2002-06-17
Abstract: Described is a polynucleotide compound comprising a polynucleotide which comprises at least one entity which upon hybridization to a complementary polynucleotide is capable of generating a detectable change in property in said hybrid, said entity being covalently or non-covalently attached by means of a linker arm to the base moiety, sugar moiety or phosphate moiety of a nucleotide in said polynucleotide, which polynucleotide compound may be used for detecting the presence of a target polynucleotide or for preventing the transcription or translation of a target polynucleotide.
Patent JP-3772609-B2 (JP)
IPC: F25D19/00
Filed: 1999-10-28
Granted: 2006-05-10
Abstract: PROBLEM TO BE SOLVED: To restrain generation of abnormal sound from a fan by stabilizing the natural frequency of the fan, concerning a fan holding structure. SOLUTION: A rotary shaft of a fan motor and a shaft for holding the fan are provided inside and outside a boss of the fan, the rotary shaft of the fan motor and the shafts inside and outside the boss are fastened at least each one part by springs and held.
Patent JP-2585407-B2 (JP)
IPC: C08G18/08
Filed: 1988-12-02
Granted: 1997-02-26
Abstract: Addition compounds suitable for use as dispersing agents and obtainable by reacting polyisocyanates having an average functionality of 2.5 to 10 with monohydroxy compounds, with compounds of formula II G-(E)n II wherein E represents -OH, -NH2 and/or -NHR (wherein R represents an alkyl group having 1 to 4 carbon atoms) and n represents 2 or 3 and G represents an aliphatic, cycloaliphatic and/or aromatic group, and with compounds of formula III Z-Q III wherein Q represents -OH, -NH2, -NHR (wherein R represents an alkyl group having 1 to 4 carbon atoms) or -SH and Z denotes a group containing at least one nitrogen-containing, basic group. The invention also relates to processes for the preparation of these addition compounds, to their use and to pulverulent or fibrous solids which are to be incorporated into liquid systems and which have been coated with these dispersing agents.
Patent JP-H07119180-B2 (JP)
IPC: C09K11/07
Filed: 1990-11-27
Abstract: Chemiluminescent mixtures utilizing tri and tetra alkyl substituted 9,10-bis(phenylethynyl)anthracene derivatives to provide higher chemiluminescence efficiencies in low temperature and high intensity-short duration applications. The preferred fluorescers are 1,2,4-trimethyl-9,10-bis(phenylethynyl) anthracene and 1,2,3,4- tetramethyl-9,10-bis(phenylethynyl)anthracene, which compounds are also part of the instant invention.
Patent JP-2706604-B2 (JP)
IPC: E04G21/14
Filed: 1992-12-21
Granted: 1998-01-28
Abstract: A multidirectional carrier and track (10) generally comprising a disc (28,30), a track (12), and a structure (20,22) on the track defining a disc supporting surface (24,26). The disc (28,30) is supported on the disc support surface (24,26) for rotation about an axis, and has first and second ball bearing assemblies (56,58). The ball bearing assemblies have inner (64,66) and outer (68,70) races, the inner races being mounted adjacent one another along the axis. The disc also has an outer cylindrical rim portion (76), the rim portion having an inner-facing surface (77), an outer-facing surface (79) and upper and lower surfaces (82,84), the inner-facing surface (77) engaging the outer races (68,70) and the lower surface (84) contacting the track (12). The structure on the inner-facing surface (77) defines axially spaced faces projecting radially inward towards the axis in step-wise fashion, forming two axially-facing shoulders (86,88) projecting from the inner-facing surface (77). The outer paces (68,70) contact the shoulders (86,88) and are held in the outer rim portion against axial movement in one direction relative to the axis of the support member. A cylindrical reinforcing band (100) surrounds and reinforces the rim portion (76). <IMAGE>
Patent JP-4344890-B2 (JP)
IPC: A61K31/506
Filed: 1998-05-28
Granted: 2009-10-14
Abstract: 2-{4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluoropyrimidine, and its physiologically acceptable salts; pharmaceutical compositions containing these compounds, and a method of treating vertigo, travel sickness, nausea, depression, anxiety, gastric acid secretion, obsessive/compulsive disorders, panic attacks or sleep apnea using these compounds are disclosed.
Patent JP-H0667789-B2 (JP)
IPC: C04B30/00
Filed: 1986-03-12
Abstract: A method of manufacturing a microporous thermally insulating body comprises mixing together a finely divided microporous insulating material such as silica aerogel or pyrogenic silica and a solid ammonia-generating compound in particulate form, and compressing the mixture to form a thermally insulating body. The ammonia-generating compound is dispersed evenly throughout the insulating material and may comprise, for example, ammonium carbonate, ammonium acetate or urea. Preferably, the ammonia-generating compound comprises a mixture of about one third by weight of ammonium carbonate and about two thirds by weight of ammonium bicarbonate together with a small proportion of magnesium oxide.
Patent JP-H037071-B2 (JP)
IPC: G01R33/00
Filed: 1980-12-19
Abstract: A magnetic amplifier sensor for measuring the magnitude and polarity of a DC current flowing in a line (10) includes a pair of saturable cores (32, 34) each having a primary (28, 30) and secondary (36, 38) winding mounted thereon. The primary coils (28, 30) are connected in series and a portion of the DC current component to be measured is diverted to a shunt circuit (16) which includes the primary windings. The secondary coils (36, 38) are connected to a push/pull type of AC source (40, 42) so that the flux levels in the cores operate in a drive/reset mode. A DC current in the primary winding (28, 30) causes a variation in the absolute magnitude of the flux levels of the two cores (32, 34) as a function of the time constant of the circuit so that during the drive interval one core saturates before the other. After rectifying, a differential signal is formed which when integrated provides an output signal whose magnitude is indicative of the magnitude DC component of current in the shunt circuit (16) and where polarity is indicative of the polarity of the DC component of current in the shunt circuit (16). A second embodiment of a magnetic amplifier sensor includes an additional winding (137, 139) on each of the saturable cores (132. 134). A portion of the output signal is fed back to the two additional windings (137, 139), which are connected in series, to provide the negative feedback for improving overall input-to-output linearity, and also for enhancing the response time of the amplifier sensor.
Patent JP-3129438-B2 (JP)
IPC: H01L29/788
Filed: 1991-11-13
Granted: 2001-01-29
Abstract: An EEPROM design featuring narrow linear electrodes including a source, a drain, a thin oxide, channel and floating gate. A pair of linear, opposed field oxide barrier walls form widthwise boundaries of the active structure which can be very closely spaced. The drain electrode, implanted in the substrate, abuts both opposed field oxide lateral walls, but does not extend under either wall. The source, drain and channel are formed in a single implant followed by diffusion after the field oxide barrier walls are formed, but prior to formation of the floating gate. All abut opposed field oxide walls in a stripe design. A control gate is disposed over the floating gate. The combination of opposed field oxide barrier walls, a stripe electrode design, and single step implant for electrode formation results in a very compact cell, utilizing a simplified EEPROM process.
Patent JP-2717830-B2 (JP)
IPC: D21F/
Filed: 1988-02-11
Granted: 1998-02-25
Abstract: Papermaking appts. has a first transfer system delivering paper from a press section to the first section of a drier, pref. having many drier rolls and vacuum rolls. A second drier section pref. also has many drier rolls and vacuum rolls and a drier transfer system passes paper from first section to second section without open draw, specifically via an unfelted drier roll. Specifically the first and second sections dry opposite sides of the paper or both dry the same side, and pref. a third section dries the opposite side.
Patent JP-3872511-B2 (JP)
IPC: A61K31/4168
Filed: 1995-07-31
Granted: 2007-01-24
Abstract: Agents useful for detecting hypoxic tumor cells are provided. The compounds have the structural formula (I)    <IMAGE>  (I)  Methods of using the compounds to detect hypoxic tumor cells are also provided, as are pharmaceutical compositions formulated with the novel compounds.
Patent JP-3093261-B2 (JP)
IPC: B01D9/02
Filed: 1991-06-12
Granted: 2000-10-03
Abstract: PCT No. PCT/BE91/00037 Sec. 371 Date Dec. 17, 1992 Sec. 102(e) Date Dec. 17, 1992 PCT Filed Jun. 12, 1991 PCT Pub. No. WO92/00130 PCT Pub. Date Jan. 9, 1992.Process and installation for crystallising an inorganic substance in a fluidised bed of crystals (14), which is generated by subjecting a solution supersaturated in the substance to be crystallised to an ascending circulation across a distributor (12), located below the bed (14), of a fluidised-bed reactor, a fraction (22) of the supersaturated solution being taken off upstream of the distributor (12) and being recycled downstream of the distributor (12) into the fluidised bed (14) or into the mother liquor from the crystallisation, and the mother liquor being supersaturated for reconstituting the said supersaturated solution.
Patent JP-3872104-B2 (JP)
IPC: F04D13/06
Filed: 1995-11-06
Granted: 2007-01-24
Abstract: A rotary pump which is suitable for use as the pump for a vehicle power steering system has an integral motor. The pump includes a housing 16 through which a rotatable shaft 4 extends having at one end a pump rotor assembly 5. The pump rotor assembly 5 is in fluid communication with an oil cavity 15 which is in good thermal contact with the housing 16. The housing 16 functions as a heat sink. Mounted on the radially outer wall of the housing 16 is the stator 20 of the motor with the stator 20 also in good thermal contact with the housing 16. The rotor 26 of the motor is located radially outside of the stator 20 and has axially arranged magnets 27. The rotor 26 is connected to the rotatable shaft 4 by means of a radially extending wall 26b. The integral rotary pump and motor is very compact and straightforward to construct and is also capable of withstanding the heat generated by the motor components during the high demands of a vehicle steering system. <IMAGE>
Patent JP-3096475-B2 (JP)
IPC: A61P1/00
Filed: 1991-09-10
Granted: 2000-10-10
Abstract: Compounds having  alpha  adrenergic activity and useful for the treatment of glaucoma, renal and gastrointestinal disorders and vasoconstictors have the formula  <IMAGE>  where R1 is independently H, or lower alkyl or 1 to 6 carbons; R2 is independently H, or lower alkyl of 1 to 6 carbons or the two R2 symbols jointly represent a carbonyl oxygen; R3 is H, lower alkyl of one to 6 carbons, O, OH and OR7 where R7 is lower alkyl of 1 to 6 carbons, or R3 is COH or COR8 where R8 is lower alkyl of 1 to 6 carbons; R4 and R5 independently is H, Br, Cl, or lower alkyl of 1 to 6 carbons, lower alkenyl or lower alkynyl with the proviso that when the R2 groups symbolize a carbonyl oxygen then R4 and R5 both cannot be hydrogen; R6 is hydrogen, Br, Cl, or lower alkyl of 1 to 6 carbons, lower alkenyl or lower alkynyl, and the R5 and the (2-imidazoline-2-yl)amino substituents are connected mutually exclusively to the 6 and 7 positions of the 1,4-benzoxazine nucleus.
Patent JP-4531865-B2 (JP)
IPC: C12N5/07
Filed: 1996-11-01
Granted: 2010-08-25
Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.
Patent JP-3880063-B2 (JP)
IPC: A61K33/242
Filed: 1994-03-18
Granted: 2007-02-14
Abstract: In accordance with the present invention, a composition and method is provided that allows the administration of a biologically-active factor to a human or animal without the normal toxic side effects by admixing the biologically-active factor and a colloidal metal such as colloidal gold or colloidal silver. The present invention can be used to treat a disease with a biologically-active factor or a combination of biologically-active factors, or can be used to safely vaccinate a human or animal against a biologically-active factor.
Patent JP-4018142-B2 (JP)
IPC: C12N15/09
Filed: 1997-01-21
Granted: 2007-12-05
Abstract: The present invention relates to the expression of various forms of a novel receptor in hematopoietic and endothelial cells. A variant form of this receptor has been detected in brain cells and shown to bind to the obese gene product, leptin. In particular, the present invention relates to methods of using leptin to stimulate the growth and development of receptor-positive hematopoietic and endothelial cells  in vitro  and  in vivo . In addition, this receptor is selectively expressed in hematopoietic progenitor cells with long-term repopulating potential. Thus, agents that specifically bind to this receptor may be used to identify and isolate progenitor cells for a variety of clinical applications.
Patent JP-4308913-B2 (JP)
IPC: B22C1/02
Filed: 1997-12-26
Granted: 2009-08-05
Abstract: The molding sand comprises hollow microspheres of aluminum silicate, preferably with an aluminum content between 15 and 45% by weight, a wall thickness between 3 and 10% of the particle diameter and a particle size between 10 and 350  mu m. These sands are useful to manufacture low density cores with good "veining" and penetration characteristics, moreover maintaining the mechanical properties of the core obtained. These cores are useful in the manufacture of iron casting.
Patent JP-3618356-B2 (JP)
IPC: A01K67/027
Filed: 1997-02-20
Granted: 2005-02-09
Abstract: A DNA fragment coding for a modified nuclear glucocorticoid receptor, particularly one mutated in the region coding for the ligand binding domain, so that receptor activity is more strongly inducible by a synthetic glucocorticoid ligand than by a natural glucocorticoid ligand, is disclosed. A recombination system inducible in mammals by means of a fusion protein produced between a recombinase and the binding domain of the ligand derived from the modified glucocorticoid receptor of which the activity is more strongly inducible by synthetic glucocorticoids than by natural glucocorticoids, is also disclosed.
Patent JP-4745469-B2 (JP)
IPC: C07D257/02
Filed: 1997-02-26
Granted: 2011-08-10
Abstract: The invention concerns a process for preparing 1,4,7,10-tetraazacyclododecane (cyclene) and its derivatives on an industrial scale by the cyclotetramerization of benzylaziridine prepared in situ.